中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
23期
12-15
,共4页
梁阔%刘爽%崔叶青%孙海晨%罗斌%万岁桂%孙雪静%李非
樑闊%劉爽%崔葉青%孫海晨%囉斌%萬歲桂%孫雪靜%李非
량활%류상%최협청%손해신%라빈%만세계%손설정%리비
皮肤移植%免疫抑制%雷公藤内酯醇%作用机制
皮膚移植%免疫抑製%雷公籐內酯醇%作用機製
피부이식%면역억제%뢰공등내지순%작용궤제
Skin transplantation%Immunosuppression%Triptolide%Mechanism
目的:探讨雷公藤内酯醇(Triptolide,Tri)在小鼠同种异体皮肤移植中的免疫抑制作用及其可能的作用机制。方法采用BALB/c小鼠作为供体,C57BL/6小鼠作为受体,建立皮肤移植模型。随机分为3组,每组8只。移植术后前6天(0~5 d)分别予腹腔注射1%吐温80溶剂(对照组)、Tri 100μg/kg(L-Tri组)和Tri 200μg/kg(H-Tri组)。术后观察移植皮片存活情况。并于术后第7天每组随机选取3只,切取脾脏以流式细胞术检测脾淋巴细胞中CD4+CD25+Foxp3+T细胞比例。结果对照组、L-Tri组和H-Tri组移植皮片平均存活时间分别为(8.3±1.2)、(12.4±1.9)、(14.9±2.2)d;脾淋巴细胞中CD4+CD25+Foxp3+调节性T细胞比例分别为(5.6±0.8)%、(12.6±1.5)%和(16.1±2.1)%;L-Tri组及H-Tri组与对照组比较,H-Tri组与L-Tri组比较,小鼠移植皮肤平均存活时间均明显延长(P<0.05),CD4+CD25+Foxp3+T细胞数量也明显增加(P<0.05)。结论 Tri能够抑制移植后排斥反应,延长小鼠同种异体皮肤移植的存活时间,其免疫作用机制可能与上调移植受体CD4+CD25+Foxp3+T细胞的比例有关,并且其免疫抑制作用具有一定的剂量依赖性。
目的:探討雷公籐內酯醇(Triptolide,Tri)在小鼠同種異體皮膚移植中的免疫抑製作用及其可能的作用機製。方法採用BALB/c小鼠作為供體,C57BL/6小鼠作為受體,建立皮膚移植模型。隨機分為3組,每組8隻。移植術後前6天(0~5 d)分彆予腹腔註射1%吐溫80溶劑(對照組)、Tri 100μg/kg(L-Tri組)和Tri 200μg/kg(H-Tri組)。術後觀察移植皮片存活情況。併于術後第7天每組隨機選取3隻,切取脾髒以流式細胞術檢測脾淋巴細胞中CD4+CD25+Foxp3+T細胞比例。結果對照組、L-Tri組和H-Tri組移植皮片平均存活時間分彆為(8.3±1.2)、(12.4±1.9)、(14.9±2.2)d;脾淋巴細胞中CD4+CD25+Foxp3+調節性T細胞比例分彆為(5.6±0.8)%、(12.6±1.5)%和(16.1±2.1)%;L-Tri組及H-Tri組與對照組比較,H-Tri組與L-Tri組比較,小鼠移植皮膚平均存活時間均明顯延長(P<0.05),CD4+CD25+Foxp3+T細胞數量也明顯增加(P<0.05)。結論 Tri能夠抑製移植後排斥反應,延長小鼠同種異體皮膚移植的存活時間,其免疫作用機製可能與上調移植受體CD4+CD25+Foxp3+T細胞的比例有關,併且其免疫抑製作用具有一定的劑量依賴性。
목적:탐토뢰공등내지순(Triptolide,Tri)재소서동충이체피부이식중적면역억제작용급기가능적작용궤제。방법채용BALB/c소서작위공체,C57BL/6소서작위수체,건립피부이식모형。수궤분위3조,매조8지。이식술후전6천(0~5 d)분별여복강주사1%토온80용제(대조조)、Tri 100μg/kg(L-Tri조)화Tri 200μg/kg(H-Tri조)。술후관찰이식피편존활정황。병우술후제7천매조수궤선취3지,절취비장이류식세포술검측비림파세포중CD4+CD25+Foxp3+T세포비례。결과대조조、L-Tri조화H-Tri조이식피편평균존활시간분별위(8.3±1.2)、(12.4±1.9)、(14.9±2.2)d;비림파세포중CD4+CD25+Foxp3+조절성T세포비례분별위(5.6±0.8)%、(12.6±1.5)%화(16.1±2.1)%;L-Tri조급H-Tri조여대조조비교,H-Tri조여L-Tri조비교,소서이식피부평균존활시간균명현연장(P<0.05),CD4+CD25+Foxp3+T세포수량야명현증가(P<0.05)。결론 Tri능구억제이식후배척반응,연장소서동충이체피부이식적존활시간,기면역작용궤제가능여상조이식수체CD4+CD25+Foxp3+T세포적비례유관,병차기면역억제작용구유일정적제량의뢰성。
Objective To investigate the immunosuppressive effect and the possible mechanism of Triptolide on skin al-lografts in murine model. Methods BALB/c mice to C57BL/6 mice skin allografting models were created. The recipi-ents were divided into three groups. The mice in the treatment groups were injected intraperitoneally with Triptolide at 100μg/kg (low-dose Triptolide group, L-Tri group) or 200 μg/kg (high-dose Triptolide group, H-Tri group) daily in the first 6 days (0-5 days);while the mice in control group were given vehicles (1% Tween 80). The median survival time of skin allografts in each group was monitored. The proportion of CD4+CD25+Foxp3+regulatory T cells in spleen tissue were tested by flow cytometry. Results The median survival time of skin allografts in the control group, L-Tri group and H-Tri group were (8.3±1.2), (12.4±1.9) d and (14.9±2.2) d respectively. The percentage of CD4+CD25+Foxp3+regulatory T cells in spleen tissues of three groups were (5.6±0.8)%, (12.6±1.5)%and (16.1±2.1)%respectively. Compared with control group, the L-Tri group and H-Tri group show significantly prolonged skin allograft survival time (P< 0.05), increased percentage of CD4+CD25+Foxp3+regulatory T cells (P< 0.05). Conclusion Tri can inhibit im-mune rejection, prolong the skin allograft survival time in mice. The anti-rejection effect of Tri may be attributed to the upregulation of regulatory T cells. In addition, the immunosuppressive effect of triptolide shows dose-dependent.